lifestyle.hoteleguide.com

Author: AC Immune SA

AC Immune First Quarter 2026 Financial and Corporate Updates

April 30, 2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease

April 30, 2026
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

April 7, 2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026

March 19, 2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

March 13, 2026
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

March 5, 2026
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

February 24, 2026